Cargando…

Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors

Multiple therapeutic agents have been developed to target the phosphatidylinositol 3-kinase (PI3K) signaling pathway, which is frequently dysregulated in cancer promoting tumor growth and survival. These include pan PI3K inhibitors, which target class Ia PI3K isoforms and have largely shown limited...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rewcastle, Gordon W, Kolekar, Sharada, Buchanan, Christina M, Gamage, Swarna A, Giddens, Anna C, Tsang, Kit Y, Kendall, Jackie D, Singh, Ripudaman, Lee, Woo-Jeong, Smith, Greg C, Han, Weiping, Matthews, David J, Denny, William A, Shepherd, Peter R, Jamieson, Stephen M.F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564600/ https://www.ncbi.nlm.nih.gov/pubmed/28537878 http://dx.doi.org/10.18632/oncotarget.17730

Ejemplares similares

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
por: Sweetlove, Melanie, et al.
Publicado: (2015)

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
por: Tran, Khanh B., et al.
Publicado: (2021)

Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo
por: Smith, Greg C., et al.
Publicado: (2012)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

PI3Kα Inhibitors That Inhibit Metastasis
por: Schmidt-Kittler, Oleg, et al.
Publicado: (2010)

Challenges in the clinical development of PI3K inhibitors
por: Massacesi, Cristian, et al.
Publicado: (2013)

PI3K inhibitors in inflammation, autoimmunity and cancer
por: Stark, Anne-Katrien, et al.
Publicado: (2015)

Phytochemicals and PI3K Inhibitors in Cancer—An Insight
por: Suvarna, Vasanti, et al.
Publicado: (2017)

PI3K inhibitors: review and new strategies
por: Zhang, Mingzhen, et al.
Publicado: (2020)

PI3K inhibitors in thrombosis and cardiovascular disease
por: Durrant, Tom N., et al.
Publicado: (2020)

Development and safety of PI3K inhibitors in cancer
por: Yu, Miaomiao, et al.
Publicado: (2023)

Selection Study for B+- -> (K-+ pi+- pi-+ pi+-)D K+- and B+- -> (K+ K- pi+ pi-)D K+-".
por: Hunt, P, et al.
Publicado: (2009)

$\pi \pi$ scattering lengths and $K \to 3\pi$ decays
por: Gallorini, Stefano
Publicado: (2013)

Roles of PI3K pan-inhibitors and PI3K-δ inhibitors in allergic lung inflammation: a systematic review and meta-analysis
por: Kim, Jong Seung, et al.
Publicado: (2020)

Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
por: Uehara, Mayuko, et al.
Publicado: (2017)

The investigation of $K^+\pi^−, \pi^+K^−$ and $\pi^+\pi^−$ atoms
por: Yazkov, Valeriy
Publicado: (2016)

Determination of the branching ratios $\Gamma(K_{L} \to 3\pi^{0}) / \Gamma(K_{L} \to \pi^{+}\pi^{-}\pi^{0})$ and $\Gamma(K_{L} \to 3\pi^{0}) / \Gamma(K_{L} \to \pi e\nu)$
por: Kreutz, A., et al.
Publicado: (1994)

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma
por: Koul, Dimpy, et al.
Publicado: (2017)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Structural Determinants of Isoform Selectivity in PI3K Inhibitors
por: Miller, Michelle S., et al.
Publicado: (2019)

Efficacy of PI3K inhibitors in advanced breast cancer
por: Verret, B, et al.
Publicado: (2019)

The present and future of PI3K inhibitors for cancer therapy
por: Castel, Pau, et al.
Publicado: (2021)

PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
por: Bou Zeid, Naji, et al.
Publicado: (2023)

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
por: Brandão, M, et al.
Publicado: (2019)

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome
por: Rao, V. Koneti, et al.
Publicado: (2023)

Study of the K+K-pi+pi- system centrally produced in the reactions pi+p --> pi+(K+K-pi+pi-)p and pp --> p(K+K-pi+pi-)p at 85 GeV/c
por: Armstrong, T A, et al.
Publicado: (1986)

Differential Effects of Phosphatidylinositol 4-Kinase (PI4K) and 3-Kinase (PI3K) Inhibitors on Stomatal Responses to Environmental Signals
por: Takahashi, Sho, et al.
Publicado: (2017)

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors
por: Rehman, Hasibur, et al.
Publicado: (2022)

Measurement of $Br(K_{S} \to \pi^{+}\pi^{-}\pi^{0})$ and limit on the CP violating decay $Br(K_{S} \to 3\pi^{0})$
por: Wache, Martin
Publicado: (2005)

Observation of $\pi^- K^+$ and $\pi^+ K^-$ atoms
por: Yazkov, Valeriy
Publicado: (2018)

$pp^{-}$ annihilation into $K^{+}K^{-}$ and $\pi^{+}\pi^{-}$
por: Witzig, Christoph
Publicado: (1991)

Observation of $\pi^- K^+$ and $\pi^+ K^-$ atoms
por: Adeva, B., et al.
Publicado: (2016)

Study of the $\overline{K} \pi \pi$ system produced in $K^{-}$ p -> $\overline{K} \pi \pi$ N reactions at 14.3 GeV/c
por: Barloutaud, R, et al.
Publicado: (1973)

Study of $\tau$ decays to $K K \pi$ and $K \pi \pi$ at LEP, with DELPHI
por: Cavallo, F R
Publicado: (1997)

The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases
por: Banham-Hall, Edward, et al.
Publicado: (2012)

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
por: Weigelt, Britta, et al.
Publicado: (2012)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Buparlisib is a brain penetrable pan-PI3K inhibitor
por: de Gooijer, Mark C., et al.
Publicado: (2018)

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
por: Hopkins, Benjamin D., et al.
Publicado: (2018)

Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
por: Hashemzadeh, Kamelia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ub1ppth7ivsvboh96u4ffo8t0u